View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 8, 2020updated 12 Jul 2022 11:48am

GSK plans to assess rheumatoid arthritis drug otilimab for Covid-19

GlaxoSmithKline (GSK) is set to study investigational rheumatoid arthritis drug otilimab for the treatment of pneumonia caused by Covid-19 infection.

GlaxoSmithKline (GSK) is set to trial an investigational rheumatoid arthritis drug otilimab for the treatment of pneumonia caused by Covid-19 infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

GSK identified the drug after screening its portfolio and pipeline for potential against Covid-19. The company acquired the rights to otilimab from German biotech firm Morphosys in 2013, noted Reuters.

According to a company spokesman, otilimab could potentially ease the effect of the coronavirus on the lungs but not suppress it directly.

The drug’s trial will enrol approximately 800 Covid-19 patients, as per website ClinicalTrials.gov. Initial data are expected to be available by the end of this year.

FierceBiotech quoted GSK as saying: “We believe that otilimab may be able to help to block the effects of one of the types of cytokine (known as GM-CSF). We plan to start a phase 2 clinical trial by the end of May.”

According to the news agency, the supply of the drug is ‘currently being used for the Covid-19 and rheumatoid arthritis trials’ but GSK will work to maximise the supply if the drug yields positive results in Covid-19 trials.

A spokesperson was quoted as saying: “We will work with regulators and manufacturing partners to determine how to provide access of otilimab to patients with Covid-19 who urgently need treatments.”

GSK initially joined Covid-19 efforts with the Coalition for Epidemic Preparedness Innovations (CEPI) alliance, under which the company agreed to provide access to its pandemic vaccine adjuvant platform to help support Covid-19 vaccine candidates.

The company also agreed to invest $250m in Vir Biotechnology for the research and development (R&D) of antibodies to treat Covid-19 infection.

Furthermore, GSK signed a letter of intent for a partnership with Sanofi to develop an adjuvanted vaccine for Covid-19.

Roche is another company studying a rheumatoid arthritis drug to treat Covid-19 pneumonia. Roche unit Genentech received US Food and Drug Administration (FDA) approval to conduct a Phase III trial of its rheumatoid arthritis drug Actemra (tocilizumab) for adults with severe Covid-19 pneumonia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena